CAMP4 Therapeutics Corporation (CAMP) Stock Statistics & Valuation Metrics

CAMP4 Therapeutics Corporation has a market cap or net worth of $240.34M. The enterprise value is $168.40M.

Market Cap

$240.34M

Enterprise Value

$168.40M

CAMP4 Therapeutics Corporation has 62,753,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

62,753,200

Owned by Insiders

20.61%

Owned by Institutions

50.82%

CAMP4 Therapeutics Corporation’s return on equity (ROE) is -1.69 and return on invested capital (ROIC) is -50.75%.

Return on Equity (ROE)

-1.69

Return on Assets (ROA)

-0.68

Return on Invested Capital (ROIC)

-50.75%

Return on Capital Employed (ROCE)

-0.51

Revenue Per Employee

72.88K

Profits Per Employee

-1.68M

Employee Count

48

Asset Turnover

0.03

Inventory Turnover

0.00

The current PE Ratio of CAMP4 Therapeutics Corporation is -1.81. CAMP4 Therapeutics Corporation’s PEG ratio is -0.10.

PE Ratio

-1.81

PS Ratio

68.24

PB Ratio

2.74

Price to FCF

-8.84

Price to Operating Cash Flow

-11.50

PEG Ratio

-0.10

In the last 12 months, CAMP4 Therapeutics Corporation had revenue of 3.50M and earned -80.40M in profits. Earnings per share was -2.65.

Revenue

3.50M

Gross Profit

1.86M

Operating Income

-52.06M

Pretax Income

-80.40M

Net Income

-80.40M

EBITDA

-50.42M

Earnings Per Share (EPS)

-2.65

In the last 12 months, operating cash flow was -28.59M and capital expenditures -129,000, giving a free cash flow of -28.72M billion.

Operating Cash Flow

-28.59M

Free Cash Flow

-28.72M

Free Cash Flow per Share

-0.33

CAMP4 Therapeutics Corporation pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-12.20%

Earnings Yield

-49.37%

Beta

1.96

52-Week Price Change

-0.80%

50-Day Moving Average

3.87

200-Day Moving Average

4.20

Relative Strength Index (RSI)

51.67

Average Volume (3m)

262.25K

CAMP4 Therapeutics Corporation upcoming earnings date is Nov 19, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 14, 2026

Next Earnings Date

Nov 19, 2026

Ex-Dividend Date

―

CAMP4 Therapeutics Corporation as a current ratio of 7.35, with Debt / Equity ratio of 4.14%

Current Ratio

7.35

Quick Ratio

7.35

Debt to Market Cap

0.01

Net Debt to EBITDA

2.13

Interest Coverage Ratio

0.00

In the past 12 months, CAMP4 Therapeutics Corporation has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

CAMP4 Therapeutics Corporation EV to EBITDA ratio is -2.07, with an EV/FCF ratio of -5.24.

EV to Sales

35.71

EV to EBITDA

-2.07

EV to Free Cash Flow

-5.24

EV to Operating Cash Flow

-5.27

CAMP4 Therapeutics Corporation has $87.13M in cash and marketable securities with $2.37M in debt, giving a net cash position of $84.76M billion.

Cash & Marketable Securities

$87.13M

Total Debt

$2.37M

Net Cash

$84.76M

Net Cash Per Share

$1.35

Tangible Book Value Per Share

-$0.01

Gross margin is 84.80%, with operating margin of -1556.74%, and net profit margin of -3539.93%.

Gross Margin

84.80%

Operating Margin

-1556.74%

Pretax Margin

-3539.93%

Net Profit Margin

-3539.93%

EBITDA Margin

-2104.62%

EBIT Margin

-1735.66%

The average price target for CAMP4 Therapeutics Corporation is $9.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$9.00

Price Target Upside

140.64% Upside

Analyst Consensus

Strong Buy

Analyst Count

7

Revenue Growth Forecast

40.21%

EPS Growth Forecast

13.40%

Smart Score

6

AI Score

48